Activated microglia and alpha 7 nicotinic acetylchorine receptors in schizophrenia: A PET study

Activated microglia and alpha 7 nicotinic acetylchorine receptors in schizophrenia: A PET study - Evaluation for activated microglia and alpha 7 nicotinic receptors using PET in schizophrenia patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024180

Enrollment

Registered

2016-10-01

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

PET, 11C-DPA713 (activated microglia) 5MBq/kg iv PET, 11C-MeQAA (alpha 7 nicotinic receptors) 5MBq/kg iv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy control - Without past or current history of psychiatric illnesses - Non-smoker Illnesses groups - Diagnosed as schizophrenia on DSM-5 - Full IQ above 70 measured with Wechsler Adult Intelligent Scale-III - Non-smoker

Exclusion criteria

Exclusion criteria: - With past or current history of serious medical illness and/or brain organic diseases - History of alcoholics or substance abuse or addiction - In pregnancy - No family support

Design outcomes

Primary

Measure	Time frame
The binding potential of both 11C-DPA713 and 11C-MeQAA in hippocampus and prefrontal cortex	—

Secondary

Measure	Time frame
cognitive function test (Cog state, TMT, stroop, VFT) Positive and Negative Symptom Scale (PANSS) brain MRI	—

Countries

Japan

Contacts

Public ContactTomoyasu Wakuda

Hamamaysu University Hospital Department of Psychiatry

wakuda@hama-med.ac.jp053-435-2295

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026